Eyes and ears

82 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Eyes and ears
Treatment and conditionWhere it standsTrials
0.25% RCI001 Ophthalmic Solution for dry eye syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
1.5 x 10^6 UC-MSC + CM for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
4D-110 for choroideremiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
5 x 10^6 UC-MSC + CM for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AAV-mediated REP1 gene replacement for choroideremiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AAV2-hRPE65v2,voretigene neparvovec-rzyl for leber congenital amaurosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AAV2-hRPE65v2,voretigene neparvovec-rzyl for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ACDN-01 for cone-rod dystrophiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ACDN-01 for stargardt diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aceclidine for myopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
Aceclidine for presbyopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Aceclidine+Brimonidine combination ophthalmic solution for myopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
Aceclidine+Brimonidine combination ophthalmic solution for presbyopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
ADVM-022 for choroidal neovascularizationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ADVM-022 for wet macular degenerationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atropine sulfate for myopiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous iPSC-derived RPE for macular degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BIIB112 for choroideremiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bimatoprost ophthalmic solution 0.01% YSBP for glaucoma, open-anglePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for corneal neovascularizationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for corneal opacityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for limbal stem cell deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo for presbyopiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brimonidine for myopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brimonidine for presbyopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brinretigene Vesgedparvovec for eye abnormalitiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brinretigene Vesgedparvovec for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brinretigene Vesgedparvovec for retinal degenerationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BS01 for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Citicoline eye drops 2% for glaucoma, open-anglePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clemastine for eye painPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CTO0308 for myopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cultured limbal stem cells Transplantation for limbal stem cell deficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DT-168 for fuchs' endothelial dystrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ER-100 epigenetic therapy for glaucoma, open-anglePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ER-100 epigenetic therapy for retinal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eyecyte-RPE™ for geographic atrophyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FEMJA transplatation for limbal stem cell deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Intensified medical follow-up and glucose-lowering drugs for retinal diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Kinezodianone R hydrochloride for glaucomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Licaminlimab for dry eye syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LinkCor Bioengineered Corneal Implant for keratoconusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LNZ101 (Aceclidine /Brimonidine) ophthalmic solution for presbyopiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nicotinamide riboside for glaucomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NT-101 ophthalmic solution for macular degenerationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose + OCU400 Med Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose + OCU400 Med Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Low Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Low Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Med Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Med Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Second Eye Dosing for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Second Eye Dosing for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU410 for geographic atrophyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OLN324 for macular degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OpRegen for geographic atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OpRegen for macular degenerationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prima for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PRIMA Bionic Vision System for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
PRIMA Products for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PRIMA Products for stargardt diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PST-611 for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Puliretgene Parvec for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
rAAV2.REP1 for choroideremiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
rAAV2.REP1 for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
rAAV2.REP1 vector for choroideremiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
RTx-015 for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SB-007 for stargardt diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SHJ002 for myopia, degenerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sirolimus for corneal dystrophies, hereditaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for dry eye syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Taurine for cataractPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band. for asthenopiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Timrepigene emparvovec for choroideremiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Vehicle for myopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Vehicle for presbyopiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Vehicle proprietary ophthalmic solution for myopiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Vehicle proprietary ophthalmic solution for presbyopiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
voretigene neparvovec-rzyl for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2